‘Optimistic’ About PGx, Lilly Taps Cabernet Pharma to Develop Targeted Rx Strategy | GenomeWeb
Eli Lilly is hoping its decision to partner with pharmacogenetics consultancy Cabernet Pharmaceuticals will improve its luck with the US Food and Drug Administration submissions, and perhaps even lead to new blockbuster drugs.
“We are optimistic that additional information on who should or should not take our new products will be viewed favorably by regulatory authorities,” Stephen Eck, Lilly’s vice-president translational medicine and PGx, told Pharmacogenomics Reporter last week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.